1988810334497112064

Membrane protein Series

Drug Target Encyclopedia Series (44) —CD28

Drug Target Encyclopedia Series (44) —CD28

CD28 is one of the most important co-stimulatory receptors in T-cell biology. Expressed on T cells, it works together with TCR/CD3 signaling to provide the second signal required for full T-cell activation, proliferation, survival, and cytokine production.

Membrane protein Series

Oct 08,2026

Drug Target Encyclopedia Series (43) —CD2

Drug Target Encyclopedia Series (43) —CD2

CD2 is not a new target in immunology. As a classic T-cell surface molecule, it has long been known for its role in T-cell adhesion, immune synapse formation, and T-cell activation. However, CD2 is now gaining renewed attention with the rise of next-generation T cell engagers (TCEs). As researchers look for ways to improve CD3-based T-cell redirection with more balanced and durable co-stimulatory signals, CD2 has re-emerged as a promising co-stimulatory axis. Recent industry progress further highlights this trend. Novartis has advanced PIT565, an anti-CD19/anti-CD2/anti-CD3 program, into clinical development, while AbbVie entered a collaboration with EvolveImmune to develop novel multispecific antibodies based on EvolveImmune’s T cell engager platform with integrated CD2 co-stimulation.

Membrane protein Series

Sep 01,2026

Drug Target Encyclopedia Series (42) —PCSK9

Drug Target Encyclopedia Series (42) —PCSK9

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a key regulator of cholesterol metabolism and plays an important role in controlling low-density lipoprotein cholesterol (LDL-C) levels. By binding to the LDL receptor (LDLR) on hepatocytes and promoting LDLR degradation, PCSK9 reduces hepatic clearance of circulating LDL-C, leading to elevated plasma cholesterol levels. Dysregulated PCSK9 activity is strongly associated with hypercholesterolemia, atherosclerosis, and cardiovascular disease, making it one of the most validated targets in lipid-lowering drug development.

Membrane protein Series

Aug 06,2026

Drug Target Encyclopedia Series (41) —BAFF

Drug Target Encyclopedia Series (41) —BAFF

BAFF, also known as B-cell Activating Factor or TNFSF13B, is a member of the TNF ligand superfamily and an important immune regulatory molecule involved in B-cell survival, maturation, and antibody production. BAFF exists as both a membrane-bound protein and a soluble cytokine, interacting with receptors including BAFF-R, TACI, and BCMA to regulate B-cell homeostasis and humoral immune responses. Dysregulated BAFF signaling is closely associated with autoimmune diseases, B-cell malignancies, and chronic inflammatory disorders.

Membrane protein Series

Jul 10,2026

Drug Target Encyclopedia Series (40) —CD80

Drug Target Encyclopedia Series (40) —CD80

CD80, also known as B7-1, is a member of the B7 family and an important immune co-stimulatory molecule involved in T-cell activation, antigen presentation, and immune response regulation. As a cell-surface ligand interacting with CD28, CTLA-4, and PD-L1, CD80 plays a dual role in balancing immune activation and immune suppression. CD80 is highly relevant in cancer immunotherapy, autoimmune disease research, transplant immunology, and inflammatory disease studies. Its central position in the immune checkpoint and co-stimulatory signaling network makes it an attractive target for next-generation immunomodulatory drug development.

Membrane protein Series

Jun 23,2026

Drug Target Encyclopedia Series (39) —CDH6

Drug Target Encyclopedia Series (39) —CDH6

CDH6, also known as **Cadherin-6**, is a calcium-dependent cell adhesion molecule involved in cell-cell interaction, tissue development, and tumor progression. With its elevated expression in several solid tumors and relatively attractive cell-surface localization, CDH6 has become an emerging target in oncology drug development, especially for antibody-based therapies. CDH6 is highly relevant in ovarian cancer, renal cell carcinoma, endometrial cancer, and other solid tumor research. Its role in tumor invasion, metastasis, and cancer progression makes it a promising membrane protein target for precision oncology strategies.

Membrane protein Series

Jun 08,2026

< 1234...8 >